TEST BANK FOR INTRODUCTORY CLINICAL
n n n n
n PHARMACOLOGY 12TH EDITION BY SUSAN FORD
n n n n n
nCHAPTER 1-54 | COMPLETE GUIDE
n n n n
, Chapter 01: General Principles of Pharmacology
n n n n n
Ford: Introductory Clinical Pharmacology 12th Edition
n n n n n
1. Afternteaching na ngroup nof nlearnersnaboutnthenbasics nofnpharmacology, nthe nlearners
nwill nbe nable nto nchoose nwhich naspect nas n the n most n critical nto nremember?
A) Drug nname
B) Drug nclass
C) Drug naction
D) Drug nsource
ACCURATE nCHOICE:-C
Reasoning n:->> nPharmacology nis nthe nstudy nof ndrugs nand nits naction non nliving
norganisms. nThus, nan nessential naspect nof npharmacology nis ndrug naction. nAn
nunderstanding nof nthe ndrug nname, ndrug nclass, nand ndrug nsource nis nimportant,
nbut nthe n most n critical naspect nrelated nto npharmacology nis n how n the ndrug nacts nin
nthe nbody.
Question n n Format:
nMultiple nChoice nChapter: n1
Learning nObj: n1 nCognitive
nLevel: nApply
Hospital nclient nNeeds: nPhysiological nIntegrity: nPharmacological
nTherapies nIntegrated nProcess: nTeaching/Learning
Reference: np. n3, nIntroduction
2. A nnursing nattendant nsuspects nthe nhospital nclient nhad nan nadverse nreaction
nto na nprescribed nmedication ndue nto nan ninteraction nwith nan nunreported n over-
the-counter nsupplement. nWhich naction nby nthe nnursing nattendant nwill nbest
nassist nin npreventing nfuture nsimilar nincidents?
A) File na nreport nwith nMedWatch
B) File na nreport nwith nthe nState nBoard nof nNursing
C) Instruct nthe nhospital nclient nto navoid ncombining nmedications nin nthe nfuture
D) Document nthe nincident nand nreport nit nto nthe nprimary nhealth ncare nprovider
ACCURATE nCHOICE:-A
Reasoning n:->> nProfessional nnurses nplay nan nimportant nrole nin nmonitoring nfor
nadverse nreactions. nTherefore, nit nis nimportant nto nsubmit nreports, neven nif nthere nis
nuncertainty nabout nthe ncause–effect nrelationship. nThe nFDA nprotects n the nidentity
nof nthose nwho nvoluntarily nreport nadverse nreactions.
Question n n Format:
nMultiple nChoice nChapter: n1
Learning nObj: n9 nCognitive
,Level: nApply
n
, Hospital nclient nNeeds: nSafe nand nEffective nCare nEnvironment: nSafety nand nInfection
nControl
Integrated nProcess: nClinical nProblem-solving nProcess n(Nursing
nProcess) n Reference: np. n7, nBox n1.1 nMedWatch nand nReporting
nAdverse nEvents
3. A nnursing nattendant nis nassessing na nhospital nclient nand nnotes nthe nhospital
nclient nhas ndeveloped nswelling nof nthe neyelids nand nlips nafter nadministration nof
na nprescribed nmedication. nWhat ndoes nthe nnursing nattendant ninterpret nthis
nfinding nto nspecifically nindicate?
A) Mild nallergic nreaction
B) Anaphylactic nshock
C) Angioedema
D) Drug nidiosyncrasy
ACCURATE nCHOICE:-C
Reasoning:->> nAngioedema nis na ntype nof nallergic ndrug nreaction nmanifested nby
nthe n collection nof nfluid nin nthe nsubcutaneous ntissues, nmost ncommonly naffecting nthe
neyelids, nlips, nmouth, nand nthroat. nAllergic nreactions ncan nbe nmanifested nby na
nwide nrange nof nsigns nand nsymptoms nsuch nas nitching, nrashes, nand nhives.
nAnaphylactic nshock nis na nserious nallergic nreaction nthat nrequires nimmediate
nmedical nattention. nDrug nidiosyncrasy ndescribes nany nunusual nor nabnormal
nreaction nto na ndrug, none nthat nis ndifferent nfrom nthe none n normally nexpected.
Question n n Format:
nMultiple nChoice nChapter: n1
Learning nObj: n5 nCognitive
nLevel: nApply
Hospital nclient nNeeds: nPhysiological nIntegrity: nReduction nof nRisk
nPotential nIntegrated nProcess: nClinical nProblem-solving nProcess
n(Nursing nProcess) nReference: np. n12, nAllergic nDrug nReactions
4. The nnursing nattendant nis npreparing nto nteach na nhospital nclient nabout na nnew
ndrug nwhich nis nin nthe nfourth nphase nof ndevelopment. nWhich nactivity nwill nthe
nnursing nattendant nexplain nbest nillustrates nthis nphase?
A) Primary nhealth ncare nproviders nreport nadverse neffects nto nFDA.
B) Healthy nvolunteers nare ninvolved nin nthe ntest.
C) In nvitro ntests nare nperformed nusing nhuman ncells.
D) The ndrug nis ngiven nto nhospital nclients nwith nthe ndisease.
ACCURATE nCHOICE:-A
n n n n
n PHARMACOLOGY 12TH EDITION BY SUSAN FORD
n n n n n
nCHAPTER 1-54 | COMPLETE GUIDE
n n n n
, Chapter 01: General Principles of Pharmacology
n n n n n
Ford: Introductory Clinical Pharmacology 12th Edition
n n n n n
1. Afternteaching na ngroup nof nlearnersnaboutnthenbasics nofnpharmacology, nthe nlearners
nwill nbe nable nto nchoose nwhich naspect nas n the n most n critical nto nremember?
A) Drug nname
B) Drug nclass
C) Drug naction
D) Drug nsource
ACCURATE nCHOICE:-C
Reasoning n:->> nPharmacology nis nthe nstudy nof ndrugs nand nits naction non nliving
norganisms. nThus, nan nessential naspect nof npharmacology nis ndrug naction. nAn
nunderstanding nof nthe ndrug nname, ndrug nclass, nand ndrug nsource nis nimportant,
nbut nthe n most n critical naspect nrelated nto npharmacology nis n how n the ndrug nacts nin
nthe nbody.
Question n n Format:
nMultiple nChoice nChapter: n1
Learning nObj: n1 nCognitive
nLevel: nApply
Hospital nclient nNeeds: nPhysiological nIntegrity: nPharmacological
nTherapies nIntegrated nProcess: nTeaching/Learning
Reference: np. n3, nIntroduction
2. A nnursing nattendant nsuspects nthe nhospital nclient nhad nan nadverse nreaction
nto na nprescribed nmedication ndue nto nan ninteraction nwith nan nunreported n over-
the-counter nsupplement. nWhich naction nby nthe nnursing nattendant nwill nbest
nassist nin npreventing nfuture nsimilar nincidents?
A) File na nreport nwith nMedWatch
B) File na nreport nwith nthe nState nBoard nof nNursing
C) Instruct nthe nhospital nclient nto navoid ncombining nmedications nin nthe nfuture
D) Document nthe nincident nand nreport nit nto nthe nprimary nhealth ncare nprovider
ACCURATE nCHOICE:-A
Reasoning n:->> nProfessional nnurses nplay nan nimportant nrole nin nmonitoring nfor
nadverse nreactions. nTherefore, nit nis nimportant nto nsubmit nreports, neven nif nthere nis
nuncertainty nabout nthe ncause–effect nrelationship. nThe nFDA nprotects n the nidentity
nof nthose nwho nvoluntarily nreport nadverse nreactions.
Question n n Format:
nMultiple nChoice nChapter: n1
Learning nObj: n9 nCognitive
,Level: nApply
n
, Hospital nclient nNeeds: nSafe nand nEffective nCare nEnvironment: nSafety nand nInfection
nControl
Integrated nProcess: nClinical nProblem-solving nProcess n(Nursing
nProcess) n Reference: np. n7, nBox n1.1 nMedWatch nand nReporting
nAdverse nEvents
3. A nnursing nattendant nis nassessing na nhospital nclient nand nnotes nthe nhospital
nclient nhas ndeveloped nswelling nof nthe neyelids nand nlips nafter nadministration nof
na nprescribed nmedication. nWhat ndoes nthe nnursing nattendant ninterpret nthis
nfinding nto nspecifically nindicate?
A) Mild nallergic nreaction
B) Anaphylactic nshock
C) Angioedema
D) Drug nidiosyncrasy
ACCURATE nCHOICE:-C
Reasoning:->> nAngioedema nis na ntype nof nallergic ndrug nreaction nmanifested nby
nthe n collection nof nfluid nin nthe nsubcutaneous ntissues, nmost ncommonly naffecting nthe
neyelids, nlips, nmouth, nand nthroat. nAllergic nreactions ncan nbe nmanifested nby na
nwide nrange nof nsigns nand nsymptoms nsuch nas nitching, nrashes, nand nhives.
nAnaphylactic nshock nis na nserious nallergic nreaction nthat nrequires nimmediate
nmedical nattention. nDrug nidiosyncrasy ndescribes nany nunusual nor nabnormal
nreaction nto na ndrug, none nthat nis ndifferent nfrom nthe none n normally nexpected.
Question n n Format:
nMultiple nChoice nChapter: n1
Learning nObj: n5 nCognitive
nLevel: nApply
Hospital nclient nNeeds: nPhysiological nIntegrity: nReduction nof nRisk
nPotential nIntegrated nProcess: nClinical nProblem-solving nProcess
n(Nursing nProcess) nReference: np. n12, nAllergic nDrug nReactions
4. The nnursing nattendant nis npreparing nto nteach na nhospital nclient nabout na nnew
ndrug nwhich nis nin nthe nfourth nphase nof ndevelopment. nWhich nactivity nwill nthe
nnursing nattendant nexplain nbest nillustrates nthis nphase?
A) Primary nhealth ncare nproviders nreport nadverse neffects nto nFDA.
B) Healthy nvolunteers nare ninvolved nin nthe ntest.
C) In nvitro ntests nare nperformed nusing nhuman ncells.
D) The ndrug nis ngiven nto nhospital nclients nwith nthe ndisease.
ACCURATE nCHOICE:-A
